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In 2019, the Innovative Medicines Initiative (IMI) funded the ConcePTION project— Building an ecosystem for better 
monitoring and communicating safety of medicines use in pregnancy and breastfeeding: validated and regulatory 
endorsed workflows for fast, optimised evidence generation— with the vision that there is a societal obligation to 
rapidly reduce uncertainty about the safety of medication use in pregnancy and breastfeeding. The present paper 
introduces the set of concepts used to describe the European data sources involved in the ConcePTION project and 
illustrates the ConcePTION Common Data Model (CDM), which serves as the keystone of the federated ConcePTION 
network. Based on data availability and content analysis of 21 European data sources, the ConcePTION CDM has 
been structured with six tables designed to capture data from routine healthcare, three tables for data from public 
health surveillance activities, three curated tables for derived data on population (e.g., observation time and mother- 
child linkage), plus four metadata tables. By its first anniversary, the ConcePTION CDM has enabled 13 data sources 
to run common scripts to contribute to major European projects, demonstrating its capacity to facilitate effective 
and transparent deployment of distributed analytics, and its potential to address questions about utilization, 
effectiveness, and safety of medicines in special populations, including during pregnancy and breastfeeding, and, 
more broadly, in the general population.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 There is a societal obligation to rapidly reduce uncertainty 
about the safety of medication use in pregnancy and breastfeed-
ing, using the framework of the heterogeneous European health 
data landscape.
WHAT QUESTION DID THIS STUDY ADDRESS?
 How can we preserve, leverage, and report on the heteroge-
neity in information provision across European data sources to 
support distributed pharmacoepidemiologic analyses of medi-
cines during pregnancy and lactation?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 This study introduces and illustrates a set of concepts to rep-
resent heterogeneity across 21 data sources and the inception of 
the ConcePTION common data model.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 The tools created within the ConcePTION ecosystem will 
support the generation of evidence on the effectiveness and 
safety of medicines during pregnancy and breastfeeding.
†Contributed equally to the work.
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More than 200 million women worldwide become preg-
nant every year,1 and a majority take at least one medication 
during pregnancy.2,3 However, merely 5% of available medi-
cations have been adequately monitored, tested, and labeled 
with safety information for use in pregnant or breastfeeding 
women.4,5 Pregnant and breastfeeding women have long been 
overlooked in medical research, especially in randomized con-
trolled clinical trials,6 due to complex practical, ethical, and 
legal challenges. Since the 2000s, data generated in routine 
healthcare have been increasingly used and recognized as a 
valuable source for evidence generation, offering the possibil-
ity of filling evidence gaps left by randomized controlled clin-
ical trials and rendering the lack of information on pregnancy 
and breastfeeding even more untenable from ethical, medical, 
and societal perspectives. In 2019, the Innovative Medicines 
Initiative (IMI) funded the ConcePTION project— Building 
an ecosystem for better monitoring and communicating safety 
of medicines use in pregnancy and breastfeeding: validated and 
regulatory endorsed workflows for fast, optimised evidence 
generation— with the vision that there is a societal obligation 
to rapidly reduce uncertainty about the safety of medication 
use in pregnancy and breastfeeding.7 ConcePTION aims to 
contribute to filling the knowledge gap regarding the effects of 
medicines in pregnancy and lactation, by developing a system 
across European Data Access Providers (DAPs) that transforms 
existing and routinely collected healthcare data into evidence 
in a robust and transparent manner.
The creation of a federated network using distributed analytics 
comes with several barriers, such as interoperability, transparency, 
data protection regulations, and ease and speed in conducting analy-
ses across multiple data sources.8 The execution of distributed multi- 
database studies using a common data model (CDM) and common 
analytics, through which analysis scripts are sent to the data rather 
than data being centralized for analysis, is one solution to these is-
sues.9,10 However, the choice of which CDM to adopt is a difficult 
and recurrent question.8,11 CDMs, such as those of the US Food 
and Drug Administration (FDA) Sentinel System,12 the National 
Patient- Centered Clinical Research Network (PCORnet),13 or the 
Observational Medical Outcomes Partnership (OMOP)14,15 have 
been used in the United States to answer public health questions 
and drug safety concerns. In Europe, several initiatives led to the 
creation of CDMs but mainly at a regional level,16 for disease- 
specific studies (e.g., EUROlinkCAT),17 or at study- specific 
level,18 and no consensus on a single CDM has yet emerged. Over 
the last 3 years, the European Health Data & Evidence Network 
(EHDEN), funded by the IMI, has supported the adoption of the 
OMOP CDM across Europe to create a federated network,19 and 
this initiative is ongoing. The extract, transform, and load (ETL) 
process of data to the OMOP CDM requires large time and finan-
cial resources, as conversion of the database structure (structural 
harmonization) and of the coding systems (semantic harmoniza-
tion) are mandatory.20 These challenges are compounded in the 
European context by heterogeneity of the data sources in terms of 
structure, provenance, and language. Fitting OMOP standards for 
all the DAPs involved in ConcePTION would have been impos-
sible without jeopardizing the forthcoming stages of the project. 
In addition, technical choices in the processing of the data have 
profound consequences on the quality of the evidence generated. 
Driven by these perspectives, the ConcePTION project’s strategy 
was to design a tailor- made CDM with the capacity to (i) preserve 
the granularity resulting from European data heterogeneity, (ii) be 
implemented within constrained timelines and budget, and (iii) 
conduct distributed analyses transparently and efficiently.
This paper aims to introduce the set of concepts used to describe 
the European data sources involved in the ConcePTION project 
and illustrates the ConcePTION CDM, which serves as the key-
stone of the federated ConcePTION network.
METHODS
Data collection and content analysis
In ConcePTION, the DAP refers to an organization with the ability and 
expertise to access, process, and analyze healthcare data to conduct phar-
macoepidemiological research. The 20 DAPs involved in ConcePTION 
were selected based on their experience and interest in conducting studies 
relating to medicines safety in pregnancy and breastfeeding, as well as 
for their expertise in making use of their data source demonstrated by 
multiple high- quality scientific publications. In Europe, DAPs generally 
access data on a project or permit basis, as they are often not the data 
custodians.
A systematic characterization of the 21 data sources accessible by the 
20 DAPs was conducted. Initially, the data sources were conceptual-
ized as relational databases, or databases that could be unambiguously 
1Bordeaux PharmacoEpi, INSERM CIC- P1401, Univ. Bordeaux, Bordeaux, France; 2Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 
Utrecht, The Netherlands; 3Agenzia regionale di sanità della Toscana, Florence, Italy; 4PharmacoEpidemiology and Drug Safety Research 
Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, 
Norway; 5Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark; 6MEMO Research, School of Medicine, University of Dundee, 
Dundee, UK; 7Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK; 8INSERM, CERPOP: SPHERE, CIC 1436, Université de 
Toulouse, Toulouse, France; 9Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 
10PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands; 11Leibniz Institute for Prevention Research and Epidemiology– BIPS, 
Bremen, Germany; 12Fundació per al Foment de la Investigació Sanitaria i Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain; 
13Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Universitat Autònoma de Barcelona, 
Bellaterra, Spain; 14IMER Registry (Emila Romagna Registry of Birth Defects), Center of Epidemiology for Clinical Research, University of Ferrara, 
Ferrara, Italy; 15Drug Policy Service, Emilia Romagna Region Health Authority, Bologna, Italy; 16Epidemiology of Rare Diseases and Congenital 
Anomalies Unit, National Research Council- Institute of Clinical Physiology (CNR- IFC), Pisa, Italy; 17Department of Biomedical and Dental Sciences 
and Morpho- functional Imaging, University of Messina, Messina, Italy; 18Department of Diagnostics and Public Health, University of Verona, Verona, 
Italy; 19Malformation Monitoring Centre Saxony- Anhalt, Medical Faculty, Otto- von- Guericke- University, Magdeburg, Germany; 20Finnish Institute for 
Health and Welfare, Helsinki, Finland; 21Faculty of Health and Life Science, Swansea University, Swansea, UK; 22Glaxosmithkline, Stevenage, UK; 
23Department Datascience and Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands. *Correspondence: Nicolas H. Thurin 
(nicolas.thurin@u-bordeaux.fr)
ARTICLE
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 0 NUMBER 0 | Month 2021 3
broken down into distinct data tables. First, the data model and the 
corresponding data dictionary accessed by each DAP were requested, in 
original format. Second, pairs of researchers from the coordinating team 
reviewed the data dictionaries. Third, each DAP was asked to produce in 
written form a high- level description of the data source they use and the 
answers to a fixed set of questions for each data table to understand key 
characteristics:
• What triggers the creation of a record in the table?
• Is the table collected for all the population of your database, or 
only for a subpopulation?
• Can you comment on the completeness and quality of the table? 
If you do not have formal measurements, feel free to convey the 
assumptions you commonly make.
• What is the time span of the table, how often it is refreshed, and 
what is the lag time between data creation and the time when the 
data has the potential to be available to your organization?
• Include other comments you may want to share about this table.
Fourth, 120- minute structured interviews were conducted with 2 
representatives from each DAP. Interviewers were instructed to review 
and clarify with the DAPs their answers to the above questions. Fifth, a 
content analysis was conducted on the interview answer documents.21,22 
Data were extracted in summary tables. DAPs revised the headers of these 
summary tables, their corresponding categories, and the populated con-
tent. The process was iterated until consensus was reached. This led to 
the identification of latent concepts that more accurately represented the 
data. Concepts were prioritized, which allowed for a concise yet exhaustive 
representation.
Design of the ConcePTION Common Data Model
A first draft of the ConcePTION CDM was created based on the basic 
requirements of pharmacoepidemiological studies in pregnancy: demo-
graphics, exposures, outcomes, healthcare encounters, procedures, death, 
and mother- child linkage. A formal comparison of this first CDM with the 
OMOP CDM version 6 was conducted, in order to align structures as much 
as possible. Wherever possible, the adoption of the OMOP conventions were 
considered to facilitate collaboration with DAPs already using the OMOP 
CDM. To verify completeness, a comparison with the FDA Sentinel System 
CDM was also conducted. The first version of the ConcePTION CDM 
was then updated to accommodate heterogeneity and specific linkages 
highlighted during DAP interviews (e.g., integration of EUROCAT tables).
RESULTS
Outcome of the content analysis
The 20 DAPs involved in ConcePTION were able to access and 
provide information on 21 data sources. The detailed information 
extracted from the interview answer documents are included in 
Supplementary Material S1.
The content analysis highlighted that a data table was too gran-
ular a unit of observation in which to deconstruct a data source. 
For instance, a pair of tables described by the Aarhus University 
contained, respectively, diagnoses and procedures from the same 
hospital stay, therefore all the answers to the interview questions 
were replicated across the two tables. The latent concepts identi-
fied after the content analysis are described in Table 1, hereafter 
referred to as the ConcePTION conceptual framework.
Table 1 ConcePTION conceptual framework
Concept Definion 
Data source 
Data bank Data bank A collecon of structured healthcare data, sustained 
by an organizaon, which mandates that a record is 
prompted whenever a specified class of events occurs 
to persons belonging to a specific populaon. 
Originator of a data 
bank 
Organizaon which mandates and sustains the data 
bank. 
Prompt of a data bank A specified class of events that prompt a record in the 
data bank. 
Underlying populaon 
of a data bank 
Records are generated whenever the prompts 
happen to a specified populaon. 
Data source A collecon of data banks having the same underlying 
populaon, or overlapping populaons, that can be 
linked to one another at an individual level. 
Data source populaon An organizaon may have access to enre data banks, 
or a subset thereof. The corresponding populaon is 
referred to as the data source populaon. 
Instance of a 
data source 
Instance of a data source Subset of a data source extracted for the purpose of 
conducng one or more studies. 
Instance populaon The subpopulaon of the data source populaon that 
is included in an instance of a data source. 
Instance of a common data model An instance of a data source converted to a Common 
Data Model. 
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Table 2 Data bank families included in at least two ConcePTION data sources
Data bank (number 




Prompts for records in the data 








Discharge from a hospitalization; 
a specialist encounter or 
























Contact between patients and 
their primary care practice: 
face- to- face/telephone/online. 
Records may be prompted when 
hospital discharge information is 
received by the practice (e.g., UK 
data banks)







status, test results, 
vaccination, dosing 











Dispensing of a medicine 
for reimbursement by a 
healthcare payer. Prompted by 
community pharmacies, hospital 
pharmacies or both, mostly 
by dispensing for outpatient 
use and/or for outpatient 
administration, rarely by 
inpatient use
National code of the 
medicinal product, 
ATC code and amount 
dispensed
Link to the 
prescription, batch 
number, condition 
of pregnancy of 
the patient, batch 
number







Live births observed in hospital 
or at the first visit of the child. 
If the prompt is delivery in 
hospital, stillbirths prompt a 
record and are distinguished 
from spontaneous abortion by 
the gestational age at labor
Information on the 
mother, on the 
pregnancy, on the 
delivery, on the 
child(ren)
















Request or execution of an 
induced termination. The record 
may be anonymous
Information on the 
circumstances of the 
termination, on the 
pregnancy and on the 
woman












involved in the 
delivery
Recording of a congenital 
anomaly, at birth or during a 
follow- up of several years; a fetal 










Civic offices Immigration/emigration in a 
country or region
Immigration/ 
emigration date, birth 
date









Registration with a healthcare 
system (primary care physician 
and/or health insurer)










Some healthcare payers admit 
exemptions from copayment due 
to some health conditions
Cause for exemption




Recording of the cause of death Principal cause of 
death
Secondary causes of 
death
ATC, Anatomic Therapeutic Chemical.
a Definition of health payers, from Donnelly et al.23: single payer refers to a health system that is financed by a single entity; in its common usage, that single 
entity is government. Examples: Italy, Denmark, Norway, Spain, and the United Kingdom. Multiple payer refers to a health system that is financed through more 
than a single entity, one of which may be governmental. Examples: Germany, the Netherlands, and France. Whether a healthcare system is single- or multiple- 
payer does not in and of itself define the system in terms of coverage. Universal coverage means simply that all people within a particular jurisdiction have 
access to healthcare, be it single- or multiple- payer. Examples: all countries in this study. b The prompts identified by the 20 DAPs are listed for each data bank 
family. However, not all prompts within a family result in creation of a record for each individual data bank within that family.
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Representation of data sources and data banks
Data banks with similar record prompts and originators were 
grouped into 10 families (see Table 2). The most common data 
bank family was Hospital Administrative Records, which is 
included in 16 out of 21 data sources; followed by Pharmacy 
Dispensing Records, included in 15 data sources. Most data 
bank families were sustained by the payer of the healthcare sys-
tem, others originated from public health or government sta-
tistical authorities. The exception was Primary Care Medical 
Records, included in five data sources: this type of data bank 
is created for clinical purposes and contains detailed clinical 
information. The most frequent record prompts resulted from: 
access to a medical facility (e.g., hospitalizations, visits to emer-
gency departments, primary care practices, or specialist clinics), 
dispensing of healthcare services (e.g., a medicinal product, a 
vaccine, a diagnostic test), accessing medical facilities due to 
pregnancy (childbirth and pregnancy loss), registering with 
healthcare services’ organization(s) (e.g., enlisting with a payer 
and immigration), or events related to population surveillance 
(e.g., death and emigration). Although record prompts were 
similar for data banks aggregated in the same family, local dif-
ferences remained. For example, among data banks belonging to 
the family Pharmacy Dispensing Records, hospital pharmacies 
may prompt records only if they dispense medicinal products 
for outpatient use, or may also include outpatient administra-
tion (e.g., infusions), or, in rare cases, also inpatient use. Among 
data banks of the family Hospital Administrative Records, cre-
ation of a record may be prompted by one or more of the fol-
lowing: hospitalization, emergency department attendance, or 
specialist appointment. Similarly, in terms of content, all the 
data banks of a single family shared a core set of data items, but 
any individual data bank may collect additional content, such as 
socio- economic status, or link between prescribing a medicinal 
product and its subsequent dispensing.
Data source and data bank characteristics are summarized in 
Supplementary Material S2, including corresponding underlying 
populations, prompts, and content. Because most data banks are 
sustained by the healthcare payer, in most data sources, the under-
lying population comprises the lawful inhabitants of a geographic 
area. This is because national healthcare systems in Europe all have 
universal coverage, which is often supported by a single payer,23 
usually a national or regional government (e.g., the UK’s National 
Health System (NHS)). In countries whose healthcare system has 
multiple payers (e.g., Germany), the underlying population of 
data banks sustained by a healthcare insurer is people registered 
with that healthcare insurer. Data sources, such as a Primary Care 
Medical Record data bank, have an underlying population defined 
by the overlap between the patients of the primary care practices 
generating the medical records and the population registered 
with the healthcare payers sustaining the other data banks repre-
senting services outside primary care. Some DAPs contributing to 
ConcePTION only access subpopulations of interest for research 
questions related to pregnancy, for example, pregnant women (e.g., 
the Centre Hospitalier Universitaire de Toulouse (CHUT)), or 
infants/fetuses with a congenital anomaly and their mothers (e.g., 
CNR- IFC).
Figure 1 shows the links between each data source and the differ-
ent families of data banks. All DAPs but one described a single data 
source; the CHUT described two. Three data sources were solely 
Congenital Anomalies Registries, and one was composed only of 
Primary Care Medical Records. All the other data sources included 
between 2 and 12 data banks, and no pair of data sources included 
the same combination of data banks. Ten data sources hosted 
one or several data bank(s) (category “Other”) that were not rep-
resented elsewhere (e.g., transport claims, cancer registries, and 
 specific outpatient claims).
ConcePTION Common data model
The ConcePTION CDM version 2.2 released in April 2021 is 
represented in Figure  2. The full sets of tables are described in 
Supplementary Material S3. The tables were divided into four 
sections:
• Routine healthcare data, accommodating data banks generated 
during routine healthcare, including Hospital Discharge Records, 
Primary Care Medical Records, and Pharmacy Dispensing Records.
• Surveillance, accommodating data banks generated from activities 
of public health surveillance (e.g., Birth Registry, Cancer Registry, 
and Death Registry), research (e.g., cohorts), and cross- sectional or 
longitudinal surveys (e.g., the Mother and Child Protection Centre 
database, accessed by the CHUT). The Congenital Anomaly 
Registry is included in this section in the standard EUROCAT 
format.24
• Curated tables, accommodate the periods of time when each per-
son in the data source population is observed. They comprise 
summary information about each person (e.g., birth date), and the 
relationships between persons in the data source population (e.g., 
mother- child relationship). These tables are mostly created based on 
Inhabitant Registries, Registration with Healthcare Systems, and 
Birth and Death Registries.
• Metadata, accommodating information about the data source (e.g., 
type of coding system used) and its specific instance (e.g., date of 
last data update), as well as details on medicinal products marketed 
in the underlying population (e.g., product identifiers and number 
of pills in a box).
Two tables of the CDM, MEDICAL_OBSERVATIONS in 
Routine healthcare data and SURVEY_OBSERVATION in 
Surveillance, have an “Entity- Attribute- Value” (EAV) structure, 
illustrated in Figure 3. An EAV table can be conceptualized as 
a table with three columns: entity is the unit of observation (in 
our case, an identifier of the original record, e.g., person_id), 
attribute is an identifier of the observable event (in our case, 
the name of the columns in the original record, e.g., height, 
weight), and value is the observable event itself (in our case, the 
content of the original column e.g., “169” for height or “63” for 
weight).25 In particular, the EAV format is suitable to load data 
banks of questionnaires, surveys, registries, or surveillance sys-
tems, or add information that does not fit in the structure of 
Routine healthcare data tables of the CDM, such as gestational 
age, delivery data, or birthweight, which are of interest for preg-
nancy and breastfeeding related studies.
Notably, each Routine healthcare and Surveillance table 
comes with origin and meaning columns, conveying the context 
that brings that record into existence: the former contains the 
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name of the data bank, the second a description of the prompt 
(e.g., discharge from hospital, or visit to the emergency depart-
ment). An updated version of the comparisons between the 
OMOP CDM version 6 and the FDA Sentinel CDM with 
the ConcePTION version 2.2 is available on Supplementary 
Material S4.
ConcePTION Vocabulary
The analysis of the interview data suggested that the CDM should be 
able to handle rich and nonstandardized data vocabularies. Thus, the 
ConcePTION vocabulary was based on a combination of the data 
banks’ dictionaries: each coded column of the ConcePTION CDM 
comes with a corresponding column indicating its dictionary. The 
dictionary may be a standardized coding system (e.g., International 
Classification of Disease 9th revision (ICD- 9) or a specific coding 
system documented in the ConcePTION vocabulary either with a 
reference to a lookup table or with explicit decoding. The vocabu-
laries of the meaning and origin columns are open: each DAP is free 
to include additional values, to capture the information that in their 
experience may be useful when processing the records for a study.
The detailed vocabulary of the ConcePTION CDM version 
2.2 is available in Supplementary Material S3.
Extract, Transform, and Load from original data banks to the 
ConcePTION CDM
To support DAPs in the ETL process, an ETL design template 
was developed defining the link between source data (original 
data banks) to the target tables of ConcePTION CDM. In this 
Figure 1 Data banks in each data source. Only data banks included in at least two data sources are represented, the others are summarized 
in “Other.” The data banks are described in Table 2.
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document, for each table and column to be populated in the 
CDM, the following information was collected: (i) the rule that 
feeds each target column based on source columns and/or context 
information, and (ii) the rule that generates target record(s) from 
each source record. The ConcePTION ETL template is available 
in Supplementary Material S5.
There is a “many- to- many relationship” between the data banks 
of a data source and the tables of the ConcePTION CDM: every 
original data bank may feed multiple target tables, and every target 
table may be fed by multiple original data banks. The most com-
mon pairs of “original data bank family– target table” are repre-
sented in Figure 4.
DISCUSSION
The qualitative analysis of 21 data sources accessed by 20 
European DAPs led to an understanding that the concepts of 
data tables and databases were insufficient to describe the land-
scape of European data, as the scope of those terms is restricted 
to information storage, whereas we need a description of how 
the information is generated, maintained, and accessed.26 
Therefore, we introduced a specific meaning for the terms 
data bank and data source: the former represents collections of 
data that are independent of a study and the latter represents 
an assimilation of data banks, where generation of observa-
tional evidence occurs. This conceptual framework allows to 
classify which prompts are included in each data source, which 
readily clarifies which data sources can provide information 
about spontaneous abortions or terminations, as well as on-
going pregnancies. This contributes in a transparent manner 
to the assessment of the suitability of data sources to address 
specific research questions. For instance, in the CONSIGN 
study,27 this allowed the investigators to understand which data 
sources could retrieve timely information on women who were 
in the early stages of pregnancy when they contracted corona-
virus disease 2019 (COVID- 19). It was found that some data 
sources were more suitable for this assessment as they con-
tained data banks with prompts that could be used to iden-
tify an ongoing pregnancy, which was not the case for all data 
sources. Together with experiences from prior projects,18,28– 33 
these concepts served as support for the development of the 
Figure 2 ConcePTION CDM version 2.2. Solid black lines refer to the linkage across records of the same person; dotted lines refer to linkage 
across items extracted from the same record; solid grey lines refer to linkage from items referring to a medicinal product to the product itself. 
Tables are color coded according to the section of the common data model they belong to: Routine healthcare data are represented in green, 
Surveillance data in dark blue, Curated data in light blue, and Metadata in grey. CDM, Common Data Model; ETL, Extract, Transform and Load.
Figure 3 Example of Entity- Attribute- Value structure. The data 
contained in the upper table is represented in the lower table as 
an Entity Attribute Value fashion. Person_id is the Entity; HEIGHT, 
WEIGHT, and GESTAGE_WEEKS are the Attributes; and, for instance, 
169 is the Value of Attribute HEIGHT for Entity P1.
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ConcePTION CDM, a generic CDM addressing the needs of 
the ConcePTION ecosystem.
The ConcePTION CDM has been specifically designed to man-
age, within constrained timelines and budget, the heterogeneity 
inherent in the diverse data banks in Europe, which vary in both 
structure and content. This capacity to align very heterogeneous 
sources and to preserve their levels of detail allows leveraging of 
specific records, such as those relating to pregnancy, which are 
Figure 4 Common ETL between original families of data banks and tables of the ConcePTION CDM version 2.2. In the Figure, each arrow 
represents a pair formed by an original family of data bank and a ConcePTION CDM target table. CDM, Common Data Model.
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challenging to explore in distributed approaches. In this context, 
technical choices may have profound consequences on the evi-
dence generated. For example, information about the start of a 
pregnancy may be captured with different types of records across 
data banks— date of last menstrual period, or gestational age in 
weeks, or gestational age in days— and all of those slightly different 
data items have to be treated in a specific way to enable the estima-
tion of an accurate date. At the same time, having this heterogene-
ity represented in a CDM allows source- specific data processing 
to be performed by a common program, which enhances transpar-
ency and reproducibility.
The absence of unique standard vocabulary is a key feature of 
the ConcePTION CDM. Absence of an a priori semantic har-
monization made CDM deployment faster and more flexible 
across Europe, because neither translation nor alignment of terms 
are required. Between May 2020 and June 2021, 13 data sources 
were converted to the ConcePTION CDM, and successfully con-
tributed to cross- national studies relying on it, including major 
European projects, such as ACCESS, where background incidence 
rates of 36 adverse events of special interest that may be used to 
monitor the benefit- risk profile of COVID- 19 vaccines were calcu-
lated.34 The preliminary results of this report contributed to regu-
latory decisions regarding the COVID- 19 AstraZeneca vaccine.35
The design of the ConcePTION CDM implies that queries to 
be executed in distributed analyses must be adapted to the cod-
ing system used in participating data sources, which is not the 
case when dealing with fully harmonized CDMs, such as OMOP 
CDM.15 When clinical phenotypes are defined across multiple 
data sources, relevant local concepts must be identified in close 
collaboration with DAPs to form ad hoc concept sets. The core 
script incorporating these concept sets can then be executed locally 
on instances of data sources mapped to the ConcePTION CDM. 
This flexible approach allows concepts to arise from different data 
banks, on a study- by- study basis: DAPs can indicate, based on their 
local knowledge and expertise, whether some concepts should be 
processed differently when retrieved from specific data banks. The 
higher the number of DAPs whose expertise must be included, the 
more time- consuming this process becomes when compared with 
querying common unique standard vocabularies. However, by sup-
porting a high level of input from DAPs, local expertise may be 
integrated at each step of data processing, generating results while 
preserving the level of detail and the quality of the information.
In addition, by capturing the specific nature and origin of rou-
tine healthcare data through the meaning and origin variables, 
the ConcePTION CDM offers the possibility of stratifying 
analyses by type of data bank or prompt, allowing investiga-
tors to quantify the differences between data sources.31,32 For 
example, a condition captured through hospital administrative 
records may differ in terms of clinical meaning from the same 
condition captured through primary care medical records: a 
discharge primary diagnosis referring to diabetes in hospital 
settings foreshadows a patient potentially more complicated 
to manage, or a more severe condition, than a diabetes diagno-
sis coded in primary care. On the other hand, if a type of data 
bank or prompt is missing in a data source, a fixed concept set 
will be less sensitive, as fewer cases are detectable. For example, 
consider a data source A, where you have a primary care medical 
record data bank and a hospital administrative record data bank, 
and data source B with hospital administrative records only, 
and consider a fixed concept set “diagnosis of diabetes.” Most 
persons with diabetes will be visiting their general practitioner 
due to their condition, which will prompt primary care medical 
records. Therefore, in data source A, this concept set will have 
high sensitivity. Fewer persons with diabetes are admitted to 
the hospital due to their condition, therefore fewer records will 
be prompted in B, hence the same concept set will have lower 
sensitivity. The impact on clinical results of the type of data 
included in analyses has been clearly observed in the ACCESS 
study.34 During background rate incidence calculation, some 
data sources were analyzed twice, using different combinations 
of data banks: Primary Care Medical Record used alone or in 
combination with Hospital Administrative data. In all data 
sources, the combination of both data banks provided consis-
tently higher estimates of incidence rates for many acute adverse 
events of special interest representing acute outcomes (e.g., acute 
kidney injury), highlighting the importance of the knowledge 
and the careful selection of the suitable type of data bank and 
prompt to generate accurate results.
There are limitations to this analysis that need to be high-
lighted. Interviews to characterize the data sources included 
in this study were conducted with one DAP per data source. 
Other DAPs may conceptualize the data sources slightly dif-
ferently based on their experiences and expertise. Nevertheless, 
this only underlines the value of utilizing the concepts presented 
here to help facilitate the thorough and transparent description 
of real- world data sources for use in studies of medicines. The 
application of the ConcePTION framework to additional data 
sources, especially outside of Europe, could further confirm the 
robustness of the concepts and capability of the CDM to ade-
quately capture the necessary information to answer drug safety 
and effectiveness questions. However, it is worth mentioning 
that evidence of the generalizability of this approach has already 
been brought in the frame of the project Metadata for data dIs-
coverability aNd study rEplicability in obseRVAtional studies 
(MINERVA)36— an activity funded by the European Medicines 
Agency to define and collect a set of metadata to describe real- 
world data sources— where it was applied to additional data 
sources, including a treatment registry and a biobank. The 
ConcePTION CDM may need continual modifications arising 
from changes to, or the addition of new information collected by 
the data banks, reflecting changes in the clinical world. However, 
our approach allows us to adapt it as needed to respond to fu-
ture emerging health concerns and to generate real- world evi-
dence in relation to these. Furthermore, the usefulness of the 
ConcePTION CDM to address concerns outside the context 
of medicine safety in pregnancy and lactation has already been 
demonstrated through the completion of the ACCESS study.34
This research, conducted in the ConcePTION project, demon-
strates the unique features of European data sources and allows their 
content to be represented in a unified conceptual framework. Based 
on this, the ConcePTION CDM was developed to facilitate effec-
tive and transparent deployment of distributed analytics, taking into 
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account the European context, and allowing the agile generation of 
answers to questions about utilization, effectiveness, and safety of 
medicines in special populations, including during pregnancy and 
breastfeeding, and, more broadly, in the general population.
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